Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

RAD51-Based HRD Test Could Help Refine Patient Selection for Olaparib in BRCA1/2- or PALB2-Mutant, HER2– Breast Cancer

December 13th 2025

RAD51 may serve as a functional biomarker to help guide olaparib use in HER2-negative metastatic breast cancer harboring BRCA1/2 or PALB2 mutations.

Neoadjuvant Niraparib Plus Dostarlimab Delivers 50% pCR Rate in BRCA+ or PALB2+ TNBC

December 12th 2025

Neoadjuvant niraparib plus dostarlimab led to pathologic complete responses in BRCA- or PALB2-mutated triple-negative breast cancer.

Dr Jänne on Selecting a Combination Regimen in First-Line EGFR+ NSCLC

December 12th 2025

Pasi A. Jänne, MD, PhD, discusses considerations for selecting a frontline combination regimen in EGFR-mutated NSCLC.

FDA Approves Niraparib/Abiraterone Acetate Plus Prednisone for BRCA2+ mCSPC

December 12th 2025

The FDA has approved niraparib and abiraterone acetate with prednisone for BRCA2-mutated mCSPC.

EMA Recommends Approval of Nogapendekin Alfa Inbakicept Plus BCG for NMIBC With CIS

December 12th 2025

The EMA recommended conditional marketing authorization for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive NMIBC with CIS.

Phase 3 STAR-221 Study of First-Line Domvanalimab/Zimberelimab Plus Chemo in Upper GI Cancers to Be Discontinued

December 12th 2025

Both the phase 3 STAR-221 trial and phase 2 EDGE-Gastric studies of domvanalimab plus zimberelimab in upper GI cancers are being discontinued.

Experts Spotlight ASH 2025 Data Poised to Change Treatment Paradigms in AML, MZL, and Myeloma

December 12th 2025

Experts reflect on pivotal data from the 2025 ASH Annual Meeting that are set to change practice in AML, MZL, FL, and multiple myeloma.

Elacestrant-Based Combinations Show Efficacy, Safety in ER+, HER2-Negative Breast Cancer

December 12th 2025

Elacestrant plus abemaciclib or everolimus was safe and showed preliminary efficacy in ER-positive, HER2-negative advanced breast cancer.

Alpelisib Plus Fulvestrant Hits Primary PFS End Point in CDK4/6 Inhibitor–Pretreated, PIK3CA-Mutant, HR+/HER2– Breast Cancer

December 12th 2025

Alpelisib plus fulvestrant improved PFS vs fulvestrant alone in PIK3CA-mutated, hormone receptor–positive/HER2-negative advanced breast cancer.

Sacituzumab Govitecan Maintains QOL Benefit Over Chemotherapy in Previously Untreated TNBC

December 10th 2025

PRO data from ASCENT-03 showed that the mean change in physical functioning from baseline to week 25 favored sacituzumab govitecan over chemotherapy.

Early Data Show Deep MRD-Negative Responses, CAR T-Cell Persistence With KLN-1010 in R/R Myeloma

December 9th 2025

The in vivo, BCMA-directed CAR T-cell therapy produced initial MRD-negative responses and persistent CAR T-cell expansion in 4 patients with relapsed/refractory myeloma.

BCMA/CD19-Directed CAR T-Cell Therapy Yields 100% ORR in Newly Diagnosed Myeloma

December 9th 2025

GC012F/AZD0120 produced responses in high-risk, transplant-eligible multiple myeloma, as well as transplant-ineligible, newly diagnosed disease.

FDA Approves Omidubicel for Adult and Pediatric Patients With Severe Aplastic Anemia

December 9th 2025

The FDA has approved the HSCT therapy for patients 6 years or older with SAA following reduced-intensity conditioning who do not have a compatible donor.

Tagraxofusp/Azacitidine/Venetoclax Triplet Is Safe, Feasible in First-Line and R/R BPDCN

December 8th 2025

Triplet therapy with tagraxofusp/azacitidine/venetoclax led to high remission rates and had a safety profile similar to that of tagraxofusp alone in BPDCN.

Acalabrutinib/Rituximab Followed by Brexu-Cel Drives Responses in Untreated High-Risk Mantle Cell Lymphoma

December 8th 2025

Acalabrutinib plus rituximab followed by brexu-cel was safe and delivered responses in previously untreated, high-risk mantle cell lymphoma.

Toripalimab Plus Chemo Maintains Survival Benefit After 6 Years in Recurrent/Metastatic NPC

December 8th 2025

The durable survival advantage seen with the regimen after 6 years of follow-up supports its use as a first-line treatment in nasopharyngeal carcinoma.

INCA033989 Nets FDA Breakthrough Therapy Designation in CALR-Mutated R/R Essential Thrombocythemia

December 8th 2025

The FDA has granted breakthrough therapy designation to INCA033989 in CALR-mutated essential thrombocythemia.

Dr Freedland on the Next Steps for Evaluating Enzalutamide in Prostate Cancer

December 8th 2025

Stephen J. Freedland, MD, discusses future avenues for research with enzalutamide in biochemically recurrent prostate cancer.

Teclistamab/Daratumumab Doublet Is Highly Effective and Tolerable for Elderly Patients With Transplant-Ineligible NDMM

December 7th 2025

The “all-antibody–based” doublet generated high VGPR or better rates and had a favorable safety profile in the front line for this patient population.

Long-Term CARTITUDE-4 Data Point to Potential Cure Fraction With Cilta-Cel in Standard-Risk R/R Myeloma

December 6th 2025

In the CARTITUDE-4 trial, 80.5% of patients with standard-risk multiple myeloma were progression-free at 2.5 years after receiving cilta-cel.